- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
Patent holdings for IPC class A61P 7/12
Total number of patents in this class: 198
10-year publication summary
|
5
|
9
|
5
|
6
|
10
|
7
|
10
|
10
|
7
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chinook Therapeutics, Inc. | 37 |
9 |
| Novo Nordisk A/S | 2266 |
6 |
| Astellas Pharma Inc. | 1121 |
5 |
| Boehringer Ingelheim International GmbH | 4748 |
4 |
| Nippon Chemiphar Co., Ltd. | 236 |
4 |
| Merck Sharp & Dohme LLC | 3750 |
4 |
| The General Hospital Corporation | 4658 |
3 |
| Takeda Pharmaceutical Company Limited | 2946 |
3 |
| Wellesley Pharmaceuticals, LLC | 24 |
3 |
| Bristol-myers Squibb Company | 4864 |
2 |
| The Regents of the University of California | 19590 |
2 |
| The Board of Trustees of the Leland Stanford Junior University | 6266 |
2 |
| Kao Corporation | 4930 |
2 |
| Abbvie Inc. | 1786 |
2 |
| Vertex Pharmaceuticals Incorporated | 1583 |
2 |
| University of Florida Research Foundation, Inc. | 3967 |
2 |
| AmideBio, LLC | 15 |
2 |
| Betta Pharmaceuticals Co., Ltd. | 179 |
2 |
| Cancer Research Technology Limited | 524 |
2 |
| Daiichi Sankyo Company, Limited | 1876 |
2 |
| Other owners | 135 |